Dunne Speaks on Medicinal Cannabis
16 March 2015
Medicinal cannabis was a hot topic at the UN Commission on Narcotic Drugs meeting in Vienna last week.
Lest there be any doubt, the debate centred around some of the properties of the cannabis plant and their potential
efficacy. No-one was suggesting that just smoking the cannabis leaf was some sort of medicinal panacea!
That highlights an important distinction in this debate – there are genuine situations to be considered, and there are
those who just want to smoke cannabis whenever they choose to. That latter group is not our concern.
However, the argument for medicinal cannabis is by no means a simple one. The evidence –worldwide – is not as clear as
it could be, nor is there any sense of commonality when it comes to the issues of dosage, methods of administration,
product standards and so on.
In New Zealand’s case, estimates of the numbers of patients likely to benefit from medicinal cannabis are very low,
which is why pharmaceutical companies have no interest in trialling products here. At the same time, for some reason,
doctors are loathe to use the existing legal provisions to recommend patients to be prescribed medicinal cannabis
products like Sativex.
I recently asked the Ministry of Health to review the issues relating to medicinal cannabis. The evidence provided was,
as I said in Vienna, quite underwhelming. So I took the opportunity there to discuss with both the United States Federal
Director of Drug Policy and Australia’s Assistant Health Minister work being done in both countries in the area of
clinical trials. In both cases, the response was similar: it is simply too early to draw definitive conclusions.
When it comes to approving new medicines, New Zealand has always adopted a rigorous, clinical trials, evidence based
approach, and it will be no different with the medicinal cannabis issue. We will gather the reputable evidence, consult
widely with other countries, and then take a decision based on the highest professional and clinical standards. That is
exactly the way we would deal with any other new medicine becoming available, and there is no credible reason or
justification for treating medicinal cannabis products in any way differently. Indeed, we would be failing the public if
we did otherwise, and exposed people to unnecessary or even unknown risks as a consequence.
This is not to suggest in any way a change in New Zealand’s current stance on leaf cannabis and its possession. But the
issue of medicinal cannabis is a highly specific and particular one we need to address in the light of new and emerging
evidence, as we receive it. We will do so against the three pillars of compassion, proportion and innovation I outlined
in Vienna, pillars which I hope will more broadly inform debate about the future direction of drug policy.
Of course, that will not satisfy those whose sole interest, dressed up in the false guise of concern for those who might
benefit from medicinal cannabis, is using cannabis recreationally. But it will ensure over time that, consistent with
the principles of our national medicines strategy I introduced in 2007, New Zealanders get access to new medicines that
are safe, affordable and effective.